Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
- PMID:7584144
- DOI: 10.1016/1074-7613(95)90125-6
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Abstract
The B7-CD28/CTLA-4 costimulatory pathway can provide a signal pivotal for T cell activation. Signaling through this pathway is complex due to the presence of two B7 family members, B7-1 and B7-2, and two counterreceptors, CD28 and CTLA-4. Studies with anti-CTLA-4 monoclonal antibodies have suggested both positive and negative roles for CTLA-4 in T cell activation. To elucidate the in vivo function of CTLA-4, we generated CTLA-4-deficient mice. These mice rapidly develop lymphoproliferative disease with multiorgan lymphocytic infiltration and tissue destruction, with particularly severe myocarditis and pancreatitis, and die by 3-4 weeks of age. The phenotype of the CTLA-4-deficient mouse strain is supported by studies that have suggested a negative role for CTLA-4 in T cell activation. The severe phenotype of mice lacking CTLA-4 implies a critical role for CTLA-4 in down-regulating T cell activation and maintaining immunologic homeostasis. In the absence of CTLA-4, peripheral T cells are activated, can spontaneously proliferate, and may mediate lethal tissue injury.
Similar articles
- Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA.Khattri R, et al.J Immunol. 1999 May 15;162(10):5784-91.J Immunol. 1999.PMID:10229811
- CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice.Tivol EA, Boyd SD, McKeon S, Borriello F, Nickerson P, Strom TB, Sharpe AH.Tivol EA, et al.J Immunol. 1997 Jun 1;158(11):5091-4.J Immunol. 1997.PMID:9164923
- B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).Mandelbrot DA, McAdam AJ, Sharpe AH.Mandelbrot DA, et al.J Exp Med. 1999 Jan 18;189(2):435-40. doi: 10.1084/jem.189.2.435.J Exp Med. 1999.PMID:9892625Free PMC article.
- The complexity of the B7-CD28/CTLA-4 costimulatory pathway.Schweitzer AN, Sharpe AH.Schweitzer AN, et al.Agents Actions Suppl. 1998;49:33-43. doi: 10.1007/978-3-0348-8857-8_6.Agents Actions Suppl. 1998.PMID:9426826Review.
- Expression and functional significance of CTLA-4, a negative regulator of T cell activation.Kosmaczewska A, Ciszak L, Boćko D, Frydecka I.Kosmaczewska A, et al.Arch Immunol Ther Exp (Warsz). 2001;49(1):39-46.Arch Immunol Ther Exp (Warsz). 2001.PMID:11266089Review.
Cited by
- Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM.Das R, et al.J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.J Immunol. 2015.PMID:25539810Free PMC article.
- Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity.Sogkas G, Atschekzei F, Adriawan IR, Dubrowinskaja N, Witte T, Schmidt RE.Sogkas G, et al.Cell Mol Immunol. 2021 May;18(5):1122-1140. doi: 10.1038/s41423-020-00626-z. Epub 2021 Apr 1.Cell Mol Immunol. 2021.PMID:33795850Free PMC article.Review.
- Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy.Cremolini C, Vitale E, Rastaldo R, Giachino C.Cremolini C, et al.Nanomaterials (Basel). 2021 Mar 8;11(3):661. doi: 10.3390/nano11030661.Nanomaterials (Basel). 2021.PMID:33800368Free PMC article.Review.
- LAG-3: from molecular functions to clinical applications.Maruhashi T, Sugiura D, Okazaki IM, Okazaki T.Maruhashi T, et al.J Immunother Cancer. 2020 Sep;8(2):e001014. doi: 10.1136/jitc-2020-001014.J Immunother Cancer. 2020.PMID:32929051Free PMC article.Review.
- Unbalanced Immune System: Immunodeficiencies and Autoimmunity.Giardino G, Gallo V, Prencipe R, Gaudino G, Romano R, De Cataldis M, Lorello P, Palamaro L, Di Giacomo C, Capalbo D, Cirillo E, D'Assante R, Pignata C.Giardino G, et al.Front Pediatr. 2016 Oct 6;4:107. doi: 10.3389/fped.2016.00107. eCollection 2016.Front Pediatr. 2016.PMID:27766253Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases